Active Ingredient Prescribing: Now Available in PrimaryClinic
Active Ingredient Prescribing functionality is now available in PrimaryClinic's Medical software, for both paper-based and e-prescribing users, thanks to a recent update to the medical management platform. Active Ingredient Prescribing (AIP) was first announced by the Australian Federal Government in the 2018-19 budget and has since become a key requirement of modern-day prescribing systems. So, what is Active Ingredient Prescribing and why is it a requirement for your practice?
What is Active Ingredient Prescribing?
Active Ingredient Prescribing is a Government initiative designed to improve consumer health literacy through ensuring consistent and standardised product descriptions for PBS and RPBS prescribed medicines.
As of February this year, the new law mandates that these prescriptions will now need to list only the active ingredient of each medication unless the prescriber specifies that the brand name should be included as well.
Why has Active Ingredient Prescribing been introduced?
Active Ingredient Prescribing has been introduced mainly for two reasons:
- Affordability: AIP encourages the uptake of generic and biosimilar medicines, promoting a health system where medicine is more financially viable in the future.
- Education and Safety: AIP ensures prescribers and patients are more aware of the active ingredients in their medications to educate and reduce patient risk.
You can find out more about AIP by reading the Safety and Quality fact sheet here.
What does your practice need to do?
The latest regulatory amendments to AIP prohibit prescribing software from automatically including brand names on prescriptions. To ensure you are compliant with the new changes, you should ensure your software is capable of following the new guidelines and has the features included as part of your everyday prescribing workflows.
The Australian Commission on Safety and Quality Health Care are responsible for managing medicine exceptions to AIP regulations, and have highlighted the following AIP exceptions:
- The medicine must be prescribed by brand, as per the List of Excluded Medicinal Items (LEMI); or
- The medicine has four or more active ingredients; or
- The prescriber needs to consider whether prescribing the medicine by brand would be clinically appropriate for the treatment of their patient as per the List of Medicines for Brand Consideration (LMBC).
For more details on AIP exceptions, click on this link.
How does this affect PrimaryClinic Medical users?
PrimaryClinic Medical users on version 4.8.0 and above are now compliant with the new AIP regulation changes. PrimaryClinic also uses MIMS medication functionality, so you will need to ensure that you have a MIMS license.
How does it work?
Within PrimaryClinic, as you search for and select a medication/drug in MIMS, Primary Clinic Medical will identify which of the following scenario's applies. It questions if the medication is:
- In the LEMI excluded medicines list;
- Has 4 or more active ingredients; or
- Is part of the LMBC list.
- None of the above.
For scenarios 1 and 2, the medication must be prescribed by brand only.
For scenario 3 (LMBC), it is the prescribers choice at point-of-care whether or not include the brand name for consideration. If they have selected the brand consideration option, then the prescription will contain the active ingredient(s) as well as the brand.
Where the above scenarios do not apply, the script will only contain the active ingredient name.
For a full video demonstration on the process of prescribing different medication, as per the different circumstances within the AIP legislation, click on the video below:
For existing customers, you can request a free upgrade by clicking on the following link: Request Upgrade